Philip Low
Founder chez On Target Laboratories LLC
Fortune : 550 440 $ au 31/03/2024
Profil
Philip S.
Low was the founder of Endocyte, Inc. founded in 1995, where he held the title of Director & Chief Science Officer from 2013 to 2018.
Dr. Low is also the founder of Eradivir, Inc., On Target Laboratories LLC, Novosteo, Inc., MorphImmune, Inc. Currently, Dr. Low is a Professor at Purdue University since 1976.
Dr. Low's former positions include being a Director at Quince Therapeutics, Inc. from 2022 to 2023 and a Principal at National Institutes of Health.
Dr. Low received his undergraduate degree from Brigham Young University and his doctorate from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 519 283 ( 1,21% ) | 550 440 $ | 31/03/2024 |
Postes actifs de Philip Low
| Sociétés | Poste | Début |
|---|---|---|
| Purdue University | Corporate Officer/Principal | 20/10/2009 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Founder | - |
On Target Laboratories LLC
 On Target Laboratories LLC BiotechnologyHealth Technology On Target Laboratories LLC develops precise and innovative small molecules whose goal is to target and illuminate cancer and other diseased tissue. The company is headquartered in Northbrook, IL. | Founder | - |
Novosteo, Inc.
 Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | Founder | - |
Anciens postes connus de Philip Low
| Sociétés | Poste | Fin |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Director/Board Member | 27/03/2023 |
| ENDOCYTE, INC. | Founder | 21/12/2018 |
Eradivir, Inc.
 Eradivir, Inc. BiotechnologyHealth Technology Eradivir, Inc. is a company that builds targeted therapeutics for infectious diseases. Eradivir spun out of a multi-year research and technology development program in Philip Low's lab in 2020. The company is based in West Lafayette, IN. The company has developed a universal platform against influenza and is now applying these technologies to SARS-CoV-2, the virus that causes COVID-19. The company was founded by Philip S. Low and Martin R. Low. | Founder | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Formation de Philip Low
| Brigham Young University | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| QUINCE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
On Target Laboratories LLC
On Target Laboratories LLC BiotechnologyHealth Technology On Target Laboratories LLC develops precise and innovative small molecules whose goal is to target and illuminate cancer and other diseased tissue. The company is headquartered in Northbrook, IL. | Health Technology |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | Health Technology |
Eradivir, Inc.
Eradivir, Inc. BiotechnologyHealth Technology Eradivir, Inc. is a company that builds targeted therapeutics for infectious diseases. Eradivir spun out of a multi-year research and technology development program in Philip Low's lab in 2020. The company is based in West Lafayette, IN. The company has developed a universal platform against influenza and is now applying these technologies to SARS-CoV-2, the virus that causes COVID-19. The company was founded by Philip S. Low and Martin R. Low. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
